Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Royalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and ...

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

Erste Group downgraded Vertex’s stock from Buy to Hold, citing concerns over high inventory and receivables ratios, despite the potential sales boost from the cystic fibrosis treatment ALYFTREK.